Recommended Reading on Myopia Management:

Bao J, Huang Y, Li X, et al. Spectacle Lenses With Aspherical Lenslets for Myopia Control vs Single-Vision Spectacle Lenses: A Randomized Clinical Trial. JAMA Ophthalmology 2022;140:472-8.

Brennan NA, Cheng X. Commonly Held Beliefs About Myopia That Lack a Robust Evidence Base. Eye Contact Lens 2019;45:215-25.

Brennan NA, Cheng X, Toubouti Y, Bullimore MA. Efficacy in Myopia Control. Prog Retin Eye Res 2021;83:100923.

Bullimore MA, Brennan NA. Juvenile-Onset Myopia—Who to Treat and How to Evaluate Success? Eye (Lond) 2023 https://doi.org/10.1038/s41433-023-02722-6.

Bullimore MA, Brennan NA. The underestimated role of myopia in uncorrectable visual impairment in the United States. Sci Rep 2023;13:15283.

Bullimore MA, Brennan NA. Efficacy in Myopia Control—The Low-Concentration Atropine for Myopia Progression (LAMP) Study. Ophthalmology 2023;130:771-2.

Bullimore MA, Brennan NA. Efficacy in Myopia Control—Does Race Matter? Optom Vis Sci 2023;100:5-8.

Bullimore MA, Brennan NA. Myopia: An Ounce of Prevention is Worth a Pound of Cure. Ophthalmic Physiol Opt 2022;43:116-121.

Bullimore MA, Ritchey ER, Shah S, Leveziel N, Bourne RRA, Flitcroft DI. The risks and benefits of myopia control. Ophthalmology 2021;128:1561-1579

Bullimore MA, Richdale K. Myopia Control 2020: Where are we and where are we heading? Ophthal Physiol Opt 2020;40:254–270.

Bullimore MA, Richdale K. Incidence of Corneal Adverse Events in Children Wearing Soft Contact Lenses. Eye Contact Lens 2023;49:204-11.

Bullimore MA, Johnson L. Overnight orthokeratology. Cont Lens Anterior Eye 2020;43:322-32.

Bullimore MA, Brennan NA. Myopia control–why every diopter matters. Optom Vis Sci 2019;96:463-465.

Bullimore MA. The safety of soft contact lenses in children. Optom Vis Sci 2017;94:638-646.

Chalmers RL, Wagner H, Mitchell GL, et al. Age and Other Risk Factors for Corneal Infiltrative and Inflammatory Events in Young Soft Contact Lens Wearers from the Contact Lens Assessment in Youth (CLAY) Study. Invest Ophthalmol Vis Sci 2011;52:6690-6.

Chamberlain P, Peixoto-de-Matos SC, Logan NS, et al. A 3-Year Randomized Clinical Trial of Misight Lenses for Myopia Control. Optom Vis Sci 2019;96:556-67.

Chamberlain P, Lazon de la Jara P, Arumugam B, Bullimore MA. Axial Length Targets for Myopia Control. Ophthalmic Physiol Opt, 2021;41:523-531.

Chua SY, Sabanayagam C, Cheung YB, et al. Age of Onset of Myopia Predicts Risk of High Myopia in Later Childhood in Myopic Singapore Children. Ophthalmic Physiol Opt 2016;36:388-94.

COMET Group. Myopia Stabilization and Associated Factors among Participants in the Correction of Myopia Evaluation Trial (COMET). Invest Ophthalmol Vis Sci 2013;54:7871-84.

Haarman AEG, Enthoven CA, Tideman JWL, et al. The Complications of Myopia: A Review and Meta-Analysis. Invest Ophthalmol Vis Sci 2020;61:49.

Hu Y, Ding X, Guo X, et al. Association of Age at Myopia Onset with Risk of High Myopia in Adulthood in a 12-Year Follow-up of a Chinese Cohort. JAMA Ophthalmology 2020.

Lam CSY, Tang WC, Tse DY, et al. Defocus Incorporated Multiple Segments (DIMS) Spectacle Lenses Slow Myopia Progression: A 2-Year Randomised Clinical Trial. Br J Ophthalmol 2020;104:363-8.

Modjtahedi BS, Abbott RL, Fong DS, et al. Reducing the Global Burden of Myopia by Delaying the Onset of Myopia and Reducing Myopic Progression in Children: The Academy's Task Force on Myopia. Ophthalmology 2021;128:816-26.

Tideman JW, Snabel MC, Tedja MS, et al. Association of Axial Length with Risk of Uncorrectable Visual Impairment for Europeans with Myopia. JAMA Ophthalmology 2016;134:1355-63.

Ueda E, Yasuda M, Fujiwara K, et al. Trends in the Prevalence of Myopia and Myopic Maculopathy in a Japanese Population: The Hisayama Study. Invest Ophthalmol Vis Sci 2019;60:2781-6.

Walline JJ, Walker MK, Mutti DO, et al. Effect of High Add Power, Medium Add Power, or Single-Vision Contact Lenses on Myopia Progression in Children: The Blink Randomized Clinical Trial. JAMA 2020;324:571-80.

Yam JC, Jiang Y, Tang SM, et al. Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control. Ophthalmology 2019;126:113-24.

Yam JC, Zhang XJ, Zhang Y, et al. Effect of Low-Concentration Atropine Eyedrops vs Placebo on Myopia Incidence in Children: The LAMP2 Randomized Clinical Trial. JAMA 2023;329:472-81.

Zadnik K, Sinnott LT, Cotter SA, et al. Prediction of Juvenile-Onset Myopia. JAMA Ophthalmology 2015;133:683-9.